echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > GZR18, a US subsidiary of Ganli Pharmaceuticals, was approved by the FDA for its clinical trial for the treatment of type 2 diabetes

    GZR18, a US subsidiary of Ganli Pharmaceuticals, was approved by the FDA for its clinical trial for the treatment of type 2 diabetes

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 6, Ganli Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary Ganli Pharmaceuticals USA had obtained the US FDA's approval for the GZR18 phase I clinical trial


    The drug is a glucagon-like peptide 1 (GLP-1) receptor agonist drug that is injected once a week.


    According to the latest data released by the International Diabetes Federation (IDF) Global Diabetes Overview 10th Edition (2020), there are currently 537 million people (20-79 years old) in the world suffering from diabetes


    According to a report released by Grand View Research, the global GLP-1 receptor agonist market share reached US$11.


    At present, the major GLP-1 receptor agonist drugs that have been approved for injection once a week around the world are dulaglycotide (Lilly), semaglutide (Novo Nordisk) and polyethylene glycol loxenatide ( Hausen, only approved in China) and so on


    As of September 30, 2021, Ganli Pharmaceutical has invested a total of 58.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.